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Summary
Introduction. Varicella,  also  known  as  chickenpox  is  one  of  the  most  common  immunizable
diseases. In 1998, the World Health Organization (WHO) recommended to incorporate this vaccine
in the national immunization programs, which Argentina did in 2015. Objectives. To describe the
behavior of the varicella time series for the 2005-2017 period, and to evaluate the impact of the
vaccine in Argentina.  Methodology.  An ecological observational study was performed, using the
varicella cases reported in the National Health Monitoring System, and the data of the National
census as secondary data sources. A model based time series analysis of the notified  varicella cases
in Argentina was performed,  using a Negative Binomial Mixed Model. For the verification of the
vaccine impact, the 2005-2014 period was selected, and a prognosis for the following years was
performed.  Impact  was evaluated by comparing the rates and confidence intervals  between the
predicted and observed values. Results. Argentina reported 1,775,587  varicella cases for the 2005-
2017 period. The series exhibited seasonality, and, a decreasing trend in the number of cases was
observed in 2016 and 2017. A  reduction of the incidence rate after  the implementation of the
vaccine  was  observed.  The  transmission  risk   decreased  in  the  country  after  vaccine
implementation.  Conclusions.  This study is the first concrete evidence of the varicella incidence
decline  after the implementation of a single dose application program in Argentina.    
Keywords:  Varicella ,  Time Series Studies,  Chickenpox Vaccine,  Health Impact  Assessment,
Public Policies.  
INTRODUCTION
Varicella, also known as chickenpox is a highly infectious disease caused by the varicella-zoster
virus (VZV), a human herpesvirus. It is an often benign, common disease in childhood, associated
to fever and generalized itchy vesicular rash, with high rates of secondary attack (1). The Attack
Rate (AT) measures the probability of occurrence of an event. Secondary Rate Attack (SRA) is the
ratio of new cases of disease among contacts exposed to a primary case. As it is characteristic of
alpha herpesvirus, VZV establishes latency after primary infection (2) (3) (4). Both varicella and
herpes zoster (HZ) are associated to a high medical, economical and social burden (5) (6).. 
Varicella has a global distribution. Certain reports describe an incidence rate of 270 per 100,000
inhabitants,  with  a  hospitalization  rate  of  3.5  per  100,000  inhabitants  in  Latin  America  (7).
However,  varicella  is  not  under  mandatory  report  in  all  countries  (8).  Argentina  reports  an
approximate rate of 250-450 cases for every 100,000 inhabitants, with children under 10 years old
as the most affected age-group, and children between 12 to 23 months, and 24 to 48 months as those
with the highest incidence rates.  In such report, 272 deaths were recorded between 1997 and 2012,
of which 60% corresponded to children under 10 years (9). 
In many countries, varicella is characterized by a seasonal pattern, and by being one of the most
common immunizable diseases. It has a strong seasonality with a maximum incidence in late spring
in  temperate  climates  and  in  the  coldest  and  driest  months  in  tropical  climates.   Likewise
differences in the epidemiology of the disease between temperate and tropical climates are different.
Argentina reports the association between the behavior of Varicella and climatic variables (10).
The implementation of public policies,  such as the systematic application of the vaccine at  the
population level, aims at reducing varicella morbidity and mortality, and at reaching a quick level of
herd  immunity.  Thus,  the  universal  and free  application  of  the  vaccine  in  children  has  a  herd
immunity effect on the non-vaccinated population (11).  
The first  vaccine was developed in 1974 by Takahashi,  from live attenuated viruses to prevent
varicella (OKA strain) (12). In 1984, GlaxoSmithKline (OKA/GSK strain) registered its vaccine in
many European countries. In 1995, Merck Sharp and Dohme (OKA/Merck strain) registered it in
the United States for use in children and healthy adults (13). It is based on a preparation made from
the OKA strain of the virus, obtained from the gallbladder of children with  varicella attenuated
through a serial propagation in cell cultures. It is highly immunogenic in susceptible children, with
a sero-conversion higher than 96% between the ages of 1 and 12 (14). 
In  1998,  the  World  Health  Organization  (WHO)  recommended  that  each  country  analyze  to
incorporate the varicella vaccine in the national vaccination programs, and the Argentinean Ministry
of Health incorporated such vaccine through the Ministerial Resolution 1,029/2014 published in the
Official Journal of July, 15 2014. Such resolution states the incorporation of the varicella vaccine in
children aged fifteen (15) months to the National Control Program of Immunizable Diseases; and
that  the  vaccine  is  universal,  free  and  mandatory  starting  from  2015  (15)  (16).  Unlike  other
countries, which comprise two vaccine doses, in Argentina a single monovalent dose is given at 15
months old, such as in Costa Rica, Ecuador, Paraguay, New Zealand and Niue (17). 
In Argentina, the live attenuated varicella-zoster virus vaccine OKA single dose strain OKA/Merck
obtained  from human  diploid  cell  cultures  WI-38 and  MRC5 has  been  used  since  2015.  It  is
administered free of  charge and universally  to  all  children aged 15 months.  In  2016, coverage
averaged 74% nationally (whole country), ranging from 46.6% in Corrientes province to 100% in
Tucumán province. In 2017, the minimum coverage was increased to 53.8% in Entre Ríos province
and several provinces exceeded 90% (18).
Once the vaccine is implemented, it is necessary to evaluate it and verify its impact. Thus, in the
present study, we aimed at evaluating the impact of the vaccine on  varicella incidence in Argentina.
The specific objectives were: 1- to describe the time series of  varicella in Argentina for the 2005-
2017 period; and 2- to evaluate the impact of the vaccine implementation in Argentina. 
Traditionally,  the evaluation of these types of public policies are made through ecological time
series studies, in which the response variable depends on its behavior in the prior periods. This
approach allows researchers to identify, explain and predict the effects of the carried-out programs
and policies in time (19). However, by definition, a series of an infectious diseases counts  exhibits
temporal dependence .Our study uses a model-based approach based on a Negative Binomial Mixed
Effects model where the temporal dependence is taken into account.  
METHODOLOGY
It was an ecological observational study performed in Argentina from 2005 to 2017. The data came
from secondary data sources: 1 - Varicella cases, defined as the number of events reported to the
national epidemiological monitoring system within the 2005-2017 period; 2 - Population data from
the 2001 and 2010 Argentinian censuses, and population projections from Instituto Nacional de
Estadísticas y Censos (INDEC) (20) (21).
The  varicella  cases  came  from  the  Argentinean  epidemiological  surveillance  system.  In  each
province  there  are  notification  nodes  that  are  homogeneously  distributed  in  each  of  province.
Physicians from the different Hospitals and Primary Health Care Centres attend to patients and
record the pathologies for which patients consult in the services. Each of these institutions functions
as a notification node. Varicella cases are mandatory to be reported. The majority of the cases are
clinically diagnosed only and are reported on a weekly basis, aggregated by age and sex, by the
notification nodes to a national level surveillance system. The consolidated data used in this study
come from national surveillance system.
For the data analyses, consisted in two steps: (i) a descriptive time series analysis of varicella cases
in Argentina; (ii) a model-based approach to verify the impact of the vaccine in Argentine.  All
analyses were performed in the R software (22).
The model-approach consisted in fit a generalized linear mixed model with a negative binomial
distribution to the number varicella cases by week. The logarithm of the expected number of cases
is given by the logarithm year population as offset, added by week and year random effects, the
week random effects can be used to represent the varicella seasonality in a given year and the year
random effects control the heterogeneity among the years and can be used to estimate a possible
trend throughout the years. The year random effects are assumed to follow a zero mean independent
Gaussian distributions with a common variance, and the week random effects is assumed to be a
cyclic second order random walk process in order to induce the temporal dependence, these random
effects  control  heterogeneity  among  years  caused  by  unmeasured  variables  such  as  climate
variation. The cyclic component is important to inform the model that the 52th week of a year
precede the first week of the following year. The model does not have an intercept, this allows us to
interpret the exponential of the week random effects as the expected number of cases by week in a
year without vaccination. The model specification is then completed by uninformative priors to the
precision  parameters  of  the  random effects  and for  the  negative  binomial  scale  parameter.  The
inference is based on the posterior distribution calculated using the INLA method (23) (24).  
For the verification of the vaccine impact, we built our model using data from the non-vaccination
period  i.e. from 2005 to 2014 . Assuming there is no annual trend on the varicella incidence, the
week random effects would represent the expected number of cases in a year without vaccination.
Year 2014 was used as a cut-off point, since the vaccine was implemented in 2015. The vaccine
impact was evaluated by comparing by year the weekly observed varicella incidence rates with the
expected  number  of  cases  assuming  no-vaccination  and  the  uncertainty  in  represented  their
respective 95% credible intervals obtained from the model. 
Among  the  ethical  considerations,  since  this  is  an  observational  study  it  does  not  imply
interventions  or  direct  contact  with  patients.  Data  confidentiality  was  respected  at  all  times,
according to the National Law N° 25,326 of personal information protection (25). In that sense, the
present  study  is  characterized  by  the  use  of  non-linked  data  and  health  records  officially
acknowledged by health authorities.  This study is approved by the Ethics Committee in Health
Research, which depends on the Ministry of Health of Tucumán, Argentina. 
RESULTS
Argentina,  reported 1,775,587 varicella cases between 2005-2017. Figure 1 presents weekly reports
of  varicella  in  the  aforementioned  period.  The  series  of  notified  cases  presents  a  seasonality
component with higher values being observed mostly on the second semester of each year, with a
first peak on the number of cases occurring approximately in July, and a second and higher peak
around October.  Before the vaccination starts,  in  2015, there is  no clear  trend and three years,
namely 2009, 2012, and 2014, were years with lower number of cases with comparison to the other
years. On the other hand, after the vaccination starts, there is a trend on reducing the number of
cases. The average number of varicella cases per year before 2015 was 146,130, and the following
years the number of reported cases were 138,053 in 2015, 96,081 in 2016, and 80,152 in 2017. 
Figure 1: Weekly varicella reported cases in Argentina from 2005 to 2017. The vertical dotted line 
indicates the beginning of the period when a single dose varicella vaccine become universally 
available to 15 month old children.
 The proposed negative binomial mixed model was fitted for the number of varicella reported cases
before 2015. In Figure 2 (a) we estimate that lowest weekly (log)-incidence occurs in week 10
(March), then it increases reaching a first peak in week 25 (July) and reaches the highest incidence
after week 40 (October). The year random effects are presented in Figure 2 (b) showing that the
years 2009, 2012 and 2014 presented a lower incidence compared to other years which do not
present a clear trend. 
Figure 2: Estimated random effects. (a) Week random effects; (b) Year random effects.
Since there is no clear yearly trend in the varicella incidence rates before 2015, we use our model
built  with  2005  to  2014  data  to  forecast  the  next  years  three  years  ahead,  i.e.  2015 to  2017,
assuming there is no vaccination. According to our model, we would expect a total of 360.4 (95%
CI 337.4; 383.4) varicella cases per 100,000 inhabitants, which is higher than observed in years
after the vaccination started. Figure 3 presents the observed incidence rates and the model-based
weekly forecasts assuming no vaccination. There is no evidence on reduction on the incidence rates
due to the vaccine introduction in 2015. However, in 2016 the number of cases was below the
expected without vaccination and the decline was more pronounced in the year of 2017 (Table 1).
This result suggests a significant decline of the varicella incidence rates in Argentina. If we compare
the observed annual incidence in 2017 with the expected incidence without vaccination we see a
reduction of approximately 50% on the incidence rates corresponding to a total of 78,580 (95% CI
68,465;  88,695)  cases  avoided.  Despite  the reduction on incidence  rates,  the periodicity  of  the
varicella  case  remains  similar  after  vaccination  with  the  incidence  rate  peak  occurring
approximately in October each year. 
Figure 3: Varicella cases after the introduction of the one dose varicella vaccine. The expected 
number of cases (black line) are the model-based estimates assuming no vaccination, the 
uncertainty around these estimates are presented in grey by the 95% CI. The coloured lines are the 
observed number of cases in 2015 (red), 2016 (blue) and 2017 (green).





2005-2009 723,239 368.1 367.3 (365.3; 369.3)
2010-2014 738,062 354.5 350.7 (348.8; 352.6)
2015 138,053 320.1 270.0 (243.7; 296.3)
2016 96,081 220.4 282.9 (242.3; 323.4)
2017 80,152 182.0 296.5 (242.0; 351.0)
Table 1. Total reported varicella cases, the observed annual incidence rate and model-based annual
incidence rates with 95% CI. For the periods 2005-2009 and 2010-2014, we present the average of
the annual incidence rates during each period.
DISCUSSION
This is  the first  study in Argentina,  and one of the few reports  in Latin America,  showing the
national  impact  of  the  implementation  of  a  single  universal  dose  of  the   varicella  vaccine.  A
description of the varicella  time series in the pre-vaccine era was obtained, and the impact of the
vaccine implementation became clear. A significant reduction of varicella  incidence rates, were
registered at the national scale. These evidences show the importance of this  type of studies to
endorse the application of public policies with scientific sound evidence.   
In many countries, the incorporation of this vaccine is not mandatory or universal. This is the case
in Japan, where before the universal immunization vaccination coverage was 40%, and varicella
infection was not controlled (26). More recent epidemiological descriptions report a sharp decrease
compared to previous years,  which coincides with the increase in coverage through a two-dose
vaccine regime resulting from governmental funding. After the implementation, evidence emerged
recommending two vaccine doses, which also reported that coverage rates were low (27). It is also
observed that countries which suspend the vaccine recommendation or gratuity exhibit an increase
on the disease incidence, with higher viral circulation (28).  
Until 2015, only nine countries had incorporated the vaccine to their schemes, and only Uruguay
(1999) and Costa Rica (2007), the first two countries to implement it, had registered its impact in
Latin America (29) (30). Argentina, like other countries, implemented the application of a single
dose  in  its  scheme  since  2015.  The  reports  of  such  countries  demonstrate  an  impact  of  the
implementation of the vaccine on incidence reduction, disease burden and hospitalizations due to
complications, as occurred with hospitalization rates due to Herpes zoster in the general population
(30) (31) (32) (33). On the other hand, evidence shows that although the vaccine is effective in
decreasing varicella   incidence,  it  might still  not be enough to prevent outbreaks  (34).  Further,
evidence shows that a single varicella  dose brings a high protection against moderate to severe
varicella , but two doses are required for an optimal protection, especially to reduce the risk of
epidemic  outbreaks  (35)  (36).  A two-dose  program  might  guarantee  a  high  effectivity  at  the
population level; however, comparative models of 1 dose versus 2 doses evidence that this depends
on the efficiency of the first dose, and on the impact that it might have on zoster (37). Likewise, the
impact  on  incidence  decrease  might  affect  specific  cohorts,  through  the  accumulation  of  the
sensitive individuals among the non-vaccinated population, who might get the disease later in their
life, as well as the behavior of the herpes zoster (HS) (38) (39). In that sense, one of the possible
impacts of mass varicella vaccination is that an increase in herpes-zoster could be expected during
the first 30 to 50 years (40).  
In terms of evidence of the effect of the vaccine on a global scale in different countries, we can cite,
for example, the United States after the implementation of the single dose vaccine in 1995, where
cases  and  rates  of  varicella  decreased  in  all  age  groups  in  surveillance  zones  with  moderate
vaccination coverage (41). In Canada, a 70% decrease in hospitalization rates was observed in all
age groups with the greatest impact on the 1-4 year age group. In Taiwan, the introduction and
widespread use of the varicella vaccine led to a 75-80% decrease in the incidence of varicella in
children.  They also report  an increase in  HZ but do not attribute  it  to  vaccination because the
increase had already been observed even before implementation. Therefore, continuous monitoring
is necessary to understand the dynamics of HZ (42). In this sense, there are revisions on a global
scale  where  herd immunity  and the absence of  a  definitive and consistent  association between
vaccination and the increase in the incidence of HZ (43) have been observed. European countries
such as Germany, Italy and Spain with a simple dose scheme, for example, also report evidence of
the impact where they declare a decrease in the incidences of Varicella in general (44) (45) (46). In
the case of African countries, there is little existing information, apart from not having the varicella
vaccine in their vaccination programs.In other countries with similar national programs to that of
Argentina, varicella  cases in pediatric patients who require hospitalizations involve mainly children
after 5 years of a single-dose vaccination (47). In 2013, the National Immunization Program of
Brazil  (NIP)  incorporated  a  live,  attenuated  tetraviral  combined  vaccine  that  includes  measles,
mumps, rubella and varicella (MMRV) in all the Brazilian states. This policy drove a reduction of
hospitalizations (48) (49). Brazil has a cost-effectiveness study of the universal vaccination program
against varicella  in childhood through a dynamic model depending on age and time to estimate
varicella  incidence during 30 years. According to the results, the program has a positive impact on
morbidity, health resources usage, and disease-related deaths (50). The model proposed a program
based on a single-dose vaccination scheme, as in Argentina. 
We can conclude that, at the global level, there is enough evidence about the effectiveness of the
vaccine when given in two doses (51) (52). Evidence also shows the absence of change in varicella
burden towards older age groups (53). In Argentina , there is information about the impact of the
disease burden in terms of associated costs, mainly of health system resources.  However, these
studies  are  based  on  theoretical  models,  unlike  this  study,  which  incorporates  varicella  cases
informed to the monitoring system (54). It is expected that costs decrease as incidence rates and
hospitalization decrease, as it occurs in other countries (55) (56) (57).
We would like to mention some limitations of the presented study. The data we use consists of
administrative  data  and  clinically  confirmed  cases  based.  There  is  no  laboratory  confirmation
leading to a possible bias due to misclassification of cases. It is an observational ecological study,
therefore  we  cannot  causally  attribute  the  reduction  of  incidence  rates  to  the  vaccine
implementation. Also, our study ignores spatial variation and possible local determinants that may
act on the incidence rates such as climate variation and different time for vaccine implementation
among  provinces.  Finally,  the  information  on  weekly  cases  for  different  age  groups  was
unavailable. It would be interesting to explore the number of cases by age groups to see the impact
of the vaccine on the target age group and also children not-vaccinated but protected due to a
possible herd immunity effect. We consider explore data by province and different age groups in
future work.
The present study is thus the first concrete evidence of the decrease in varicella  incidence with a
single-dose application program. 
Recommendations
Epidemiological  monitoring  is  a  first  step  towards  the  evaluation  of  the  single-dose  program
effectiveness,  and the  potential  need of  a  second vaccine  dose.  Further  studies  are  required  to
evaluate the duration and intensity of the vaccine implementation effect, as well  as the indirect
effect  on  non-vaccinated  age  groups.  It  is  also  convenient  to  perform  a  new  cost  study,
incorporating  the  information  derived  from  this  research,  and  to  study  the  impact  in  all  the
Argentine  provinces.  These  results  could  derive  in  important  implications  for  the  current
vaccination policies.  
Prevention, through the implementation of programs based on laws is the action of higher impact on
public health (58). An example of this is the vaccine implementation and the tasks carried out by the
National Program of Control of Immunizable Diseases (NPCID). The objective of such program is
to ensure coverage levels,  especially under complex situations that countries might face,  where
vaccination coverages might become reduces due to discontinuations of this type of policies. For
that reason, it is important that these public policies are reinforced and continue all political, social
or economic contexts (59). On the other hand, and in agreement with the aforementioned facts, it is
key to continue supporting strategies that derive in quality records both of health events and of
coverage date, since they constitute the basis for generating of public policy impact. 
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Highlights
 Evidencing the impact of the vaccine implementation in Argentina. 
 Describing the disease in the pre-vaccination era. 
 First monitoring of the post-vaccination era at the national scale.  
 Showing the performance of the vaccination program. 
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